+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Drugs Market by Drug Class (Biguanides, DPP-4 Inhibitors, GLP-1 Receptor Agonists), Route Of Administration (Injectable, Oral), Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast 2025-2030- Product Image
Type 2 Diabetes Drugs Market by Drug Class (Biguanides, DPP-4 Inhibitors, GLP-1 Receptor Agonists), Route Of Administration (Injectable, Oral), Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast 2025-2030- Product Image
Sale

Type 2 Diabetes Drugs Market by Drug Class (Biguanides, DPP-4 Inhibitors, GLP-1 Receptor Agonists), Route Of Administration (Injectable, Oral), Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666390
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global Type 2 Diabetes Drugs Market is experiencing accelerated transformation, as pharmaceutical innovation and digital integration reshape treatment approaches. Senior leaders navigating this space must reconcile multiple pressures—including evolving therapies, complex care models, and regulatory shifts—to capture sustainable value.

Market Snapshot: Type 2 Diabetes Drugs Market Dynamics

The Type 2 Diabetes Drugs Market grew from USD 77.07 billion in 2024 to USD 84.07 billion in 2025. It is expected to continue growing at a CAGR of 8.91%, reaching USD 128.67 billion by 2030. This trajectory reflects increased disease prevalence, a broader therapeutic toolkit, and shifts in patient and healthcare priorities. Such momentum is further fueled by the interplay of demographic change, advancements in molecular science, and persistent demand for tailored diabetes management solutions.

Scope & Segmentation of the Type 2 Diabetes Drugs Market

This research comprehensively analyzes the landscape, detailing core segments and pivotal growth enablers that shape strategies. Understanding the following is essential for effective positioning:

  • Drug Classes: Includes biguanides, DPP-4 inhibitors, GLP-1 receptor agonists, insulins (basal, prandial, premixed), SGLT2 inhibitors, sulfonylureas, and thiazolidinediones, highlighting key active molecules and formulation advancements.
  • Route of Administration: Oral therapies (tablets, capsules) and injectables (pen devices, prefilled syringes) offer options tailored to clinical setting and patient preference.
  • Treatment Lines: Differentiates first-line monotherapies, combination options, and escalation to second- or third-line therapies, based on patient response and glycemic control needs.
  • Distribution Channels: Market access occurs through hospital, retail, and online pharmacy networks, each marked by unique logistics and reimbursement patterns.
  • Brand Types: Covers branded and generic drug adoption, tied to payer strategies, patient affordability, and patent cycles.
  • Patient Demographics: Segmentation includes age groups (18–65, above 65 years) and gender (male, female), aligning offerings with key population subsets.
  • Geographies Analyzed: Regional coverage spans Americas, EMEA, and Asia Pacific, highlighting localized market behavior and regulatory factors.
  • Technology Integration: Evaluation includes adoption of continuous glucose monitoring, AI-powered digital therapeutics, and remote patient engagement tools.

Key Takeaways for Senior Decision-Makers

  • Pharmaceutical companies are expanding partnerships with technology providers to deliver integrated care, blending pharmacological therapies with digital adherence and coaching platforms.
  • Patient-centric models are replacing traditional care pathways, with a shift toward individualized regimens informed by real-world data and analytics.
  • Regulatory and policy complexities, especially in emerging markets, are shaping both pricing strategies and manufacturing localization.
  • The market continues to see increased competition between established leaders and agile biotechs introducing biosimilars and differentiated formulations, expanding treatment access and driving innovation.
  • Regional disparities in healthcare infrastructure and reimbursement frameworks require adaptable, locally informed go-to-market approaches.
  • Value differentiation is increasingly tied to demonstrable patient outcomes and supply chain resilience, rather than product feature alone.

Tariff Impact on Type 2 Diabetes Drug Supply and Access

The introduction of United States pharmaceutical tariffs in early 2025 has impacted sourcing and logistics strategies for Type 2 diabetes drugs. Companies have diversified manufacturing locations and renegotiated supplier arrangements to limit exposure to border costs. These adaptations enhance inventory turnover and continuity of supply, ensuring therapies reach patients despite regulatory disruptions. High-level dialogues between industry and policymakers have also intensified, exploring tariff relief for critical medications and facilitating public health safeguards.

Methodology & Data Sources

Our methodology combines qualitative interviews with industry executives and healthcare practitioners, enriched by secondary research from regulatory filings and industry publications. Competitive intelligence is built through patent reviews and pipeline analyses, while demographics and adoption are mapped using public health data and scenario planning.

Why This Report Matters

  • Guides strategic investment by aligning offerings with robust, data-driven market segmentation and emerging therapy trends.
  • Enables senior leaders to anticipate and proactively respond to evolving tariff policies, localization needs, and regulatory challenges.
  • Supports outcome-focused decision making by spotlighting real-world evidence, technology integration, and agile partnership models across key growth regions.

Conclusion

The Type 2 Diabetes Drugs Market is defined by multifaceted innovation, operational shifts, and adaptive strategies for diverse geographies. Organizations that combine clinical excellence with digital solutions and resilient supply chains will be positioned to achieve long-term growth and improved patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising prominence of dual GIP/GLP-1 receptor agonists demonstrating superior glycemic control and weight loss
5.2. Increased adoption of SGLT2 inhibitors for cardiovascular and renal protection beyond glycemic management
5.3. Emergence of personalized diabetes management through continuous glucose monitoring integrated with AI-driven insulin dosing
5.4. Growing focus on oral semaglutide formulations to enhance patient convenience and adherence in type 2 diabetes
5.5. Regulatory approvals for once-weekly basal insulin analogs offering improved fasting glucose stability and patient convenience
5.6. Development of glucose-responsive insulin technologies aimed at reducing hypoglycemia risk and improving quality of life
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 2 Diabetes Drugs Market, by Drug Class
8.1. Introduction
8.2. Biguanides
8.2.1. Combination Formulations
8.2.2. Extended Release
8.2.3. Immediate Release
8.3. DPP-4 Inhibitors
8.3.1. Alogliptin
8.3.2. Linagliptin
8.3.3. Saxagliptin
8.3.4. Sitagliptin
8.4. GLP-1 Receptor Agonists
8.4.1. Dulaglutide
8.4.2. Exenatide
8.4.3. Liraglutide
8.4.4. Semaglutide
8.5. Insulin
8.5.1. Basal
8.5.1.1. Degludec
8.5.1.2. Detemir
8.5.1.3. Glargine
8.5.2. Prandial
8.5.2.1. Aspart
8.5.2.2. Glulisine
8.5.2.3. Lispro
8.5.3. Premixed
8.5.3.1. 50/50 Mix
8.5.3.2. 70/30 Mix
8.5.3.3. 75/25 Mix
8.6. SGLT2 Inhibitors
8.6.1. Canagliflozin
8.6.2. Dapagliflozin
8.6.3. Empagliflozin
8.6.4. Ertugliflozin
8.7. Sulfonylureas
8.7.1. Chlorpropamide
8.7.2. Glimepiride
8.7.3. Glipizide
8.7.4. Glyburide
8.8. Thiazolidinediones
8.8.1. Pioglitazone
8.8.2. Rosiglitazone
9. Type 2 Diabetes Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Pen
9.2.2. PreFilled Syringe
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
10. Type 2 Diabetes Drugs Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.2.1. Combination
10.2.1.1. Dual Therapy
10.2.1.2. Triple Therapy
10.2.2. Monotherapy
10.3. Second Line
10.4. Third Line
11. Type 2 Diabetes Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Type 2 Diabetes Drugs Market, by Brand Type
12.1. Introduction
12.2. Branded
12.3. Generic
13. Type 2 Diabetes Drugs Market, by Patient Age Group
13.1. Introduction
13.2. 18 To 65
13.3. Above 65
14. Type 2 Diabetes Drugs Market, by Patient Gender
14.1. Introduction
14.2. Female
14.3. Male
15. Americas Type 2 Diabetes Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Type 2 Diabetes Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Type 2 Diabetes Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novo Nordisk A/S
18.3.2. Eli Lilly and Company
18.3.3. Sanofi S.A.
18.3.4. Merck & Co., Inc.
18.3.5. AstraZeneca PLC
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Johnson & Johnson
18.3.8. Pfizer Inc.
18.3.9. Novartis AG
18.3.10. Daiichi Sankyo Company, Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. TYPE 2 DIABETES DRUGS MARKET: RESEARCHAI
FIGURE 30. TYPE 2 DIABETES DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. TYPE 2 DIABETES DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. TYPE 2 DIABETES DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 18 TO 65, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ABOVE 65, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY MALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 263. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
TABLE 266. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2030 (USD MILLION)
TABLE 267. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 270. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 271. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 272. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 273. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
TABLE 274. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2030 (USD MILLION)
TABLE 275. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
TABLE 276. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2030 (USD MILLION)
TABLE 277. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
TABLE 278. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2030 (USD MILLION)
TABLE 279. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
TABLE 282. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2030 (USD MILLION)
TABLE 283. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
TABLE 284. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2030 (USD MILLION)
TABLE 285. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 288. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 289. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 290. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 291. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 292. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 293. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 294. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 295. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
TABLE 296. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2030 (USD MILLION)
TABLE 297. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 300. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 301. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 302. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 303. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2018-2024 (USD MILLION)
TABLE 304. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2025-2030 (USD MILLION)
TABLE 305. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 306. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 307. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
TABLE 308. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2030 (USD MILLION)
TABLE 309. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 310. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 311. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 312. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 313. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
TABLE 314. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2030 (USD MILLION)
TABLE 315. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
TABLE 316. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2030 (USD MILLION)
TABLE 317. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
TABLE 318. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2030 (USD MILLION)
TABLE 319. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
TABLE 320. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2030 (USD MILLION)
TABLE 321. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 322. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 323. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
TABLE 324. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2030 (USD MILLION)
TABLE 325. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
TABLE 326. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2030 (USD MILLION)
TABLE 327. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 330. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 331. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 332. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 333. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 20

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Type 2 Diabetes Drugs market report include:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Daiichi Sankyo Company, Limited

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 84.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 128.67 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diabetes Drugs Market by Drug Class (Amylin Analogs, GLP-1 Receptor Agonists, Insulin), Route Of Administration (Inhalation, Injectable, Oral), Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2025-2030 - Product Image

Diabetes Drugs Market by Drug Class (Amylin Analogs, GLP-1 Receptor Agonists, Insulin), Route Of Administration (Inhalation, Injectable, Oral), Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030 - Product Image

Pediatric Diabetes Therapeutic Market Size, Share and Trends Analysis Report by Type (Type 1, Type 2), Treatment (Insulin, GLP-1, Biguanide, SGLT2), Route of Administration, Distribution Channel, and Region 2024-2030

  • Report
  • 110 Pages
  • Global
From
Type 2 Diabetes Drug Pipeline Analysis Report 2025 - Product Image

Type 2 Diabetes Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034 - Product Image

Global Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034

  • Report
  • 300 Pages
  • Global
From

About the Type 2 Diabetes Drug Market

The Type 2 Diabetes Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat Type 2 Diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin properly. Type 2 Diabetes Drugs are used to help control blood sugar levels, reduce the risk of complications, and improve overall health. These drugs can be taken orally, injected, or inhaled. Common Type 2 Diabetes Drugs include Metformin, Sulfonylureas, Thiazolidinediones, Meglitinides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors. Some companies in the Type 2 Diabetes Drug market include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, Boehringer Ingelheim, and Takeda. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.